Skip to main content
Top
Published in: BMC Pediatrics 1/2024

Open Access 01-12-2024 | Iron Deficiency Anemia | Research

Erythroferrone and hepcidin levels in children with iron deficiency anemia

Authors: Ramazan Dulkadir, Gamze Turna Saltoğlu, Ali Güneş

Published in: BMC Pediatrics | Issue 1/2024

Login to get access

Abstract

Background

Iron deficiency anemia remains a significant public health issue in developing countries. The regulation of iron metabolism is primarily controlled by hepcidin, a key regulatory protein. During erythropoiesis, erythroferrone (ERFE), a hormone produced by erythroblasts in response to erythropoietin (EPO) synthesis, mediates the suppression of hepcidin. In this study, it was aimed to determine the correlation between erythroferrone (ERFE) and hepcidin levels in children with iron deficiency anemia.

Methods

This is a case-control study conducted at Kırşehir Ahi Evran University Training and Research Hospital Pediatrics Clinic between 1 and 31 September 2020. The study included 26 healthy children and 26 children with iron deficiency anemia. In order to evaluate iron status,whole blood count, serum iron, total iron binding capacity (TIBC), and ferritin levels were analyzed. The study measured the levels of hepcidin and erythroferrone in the serum of children diagnosed with iron deficiency before and after one month of iron treatment, as well as in a control group, using the ELISA method. Correlation between whole blood count, initial ferritin, hepcidin, ERFE and ferritin in the iron deficiency group was evaluated.

Results

Compared with healthy controls, the iron-deficient group had significantly lower haemoglobin (p < 0.001), MCV (p = 0.001), MCH (p < 0.001), MCHC (p < 0.001), iron (p < 0.001), ferritin (p < 0.001) and hepcidin (p = 0.001). Ferritin and hepcidin levels increased while erythroferrone levels remained unchanged after iron deficiency treatment. There was no correlation between hepcidin and ferritin levels in treatment group.

Conclusions

The study found a strong and positive correlation between ferritin and hepcidin levels in iron-deficient children, but not between ERFE levels, suggesting that hepcidin is largely regulated by iron deposition levels. In addition, there was an increase in ferritin and hepcidin levels after iron treatment. The study found no significant difference in erythroferrone levels between the iron-deficient group and the control group. It is thought that this may be due to the short duration of iron treatment given to the patients with iron deficiency anemia included in the study.
Literature
1.
go back to reference Sandoval C, ApproachtothechildwithanemiaUptodate. http://www.uptodate.com Yayınlanma tarihi: Haziran 2019. Erişim tarihi 22 Nisan 2020. Sandoval C, ApproachtothechildwithanemiaUptodate. http://​www.​uptodate.​com Yayınlanma tarihi: Haziran 2019. Erişim tarihi 22 Nisan 2020.
2.
go back to reference Diagnosis. and Treatment guideline for iron deficiency anemia in children. Turkish Society of Hematology; National Treatment Guidelines; 2011. Diagnosis. and Treatment guideline for iron deficiency anemia in children. Turkish Society of Hematology; National Treatment Guidelines; 2011.
3.
go back to reference Özdemir N. Iron deficiency anemia from diagnosis to treatment in children. TürkPed Arş. 2015;50:11–9.CrossRef Özdemir N. Iron deficiency anemia from diagnosis to treatment in children. TürkPed Arş. 2015;50:11–9.CrossRef
4.
go back to reference Oski F. Irondeficiency in infancyandchildhood.In: Desforges J(ed)New Eng J Med. 1993; 15; 329(3):190-3. Oski F. Irondeficiency in infancyandchildhood.In: Desforges J(ed)New Eng J Med. 1993; 15; 329(3):190-3.
8.
go back to reference World HealthOrganization. Irondeficiencyanaemiaassessment, prevention, andcontrol. A guideforprogrammemanagers. Geneva (Switzerland): World HealthOrganization; 2001. World HealthOrganization. Irondeficiencyanaemiaassessment, prevention, andcontrol. A guideforprogrammemanagers. Geneva (Switzerland): World HealthOrganization; 2001.
9.
go back to reference Oski FA, Brugnara C, Nathan DG. A diagnosticapproachtotheanemicpatient. In: Nathan DG, Orkin SH, editors. NathanandOski’shematology of infancyandchildhood. 5th ed. Philadelphia, PA: W.B. SaundersCo; 1998. pp. 375–84. Oski FA, Brugnara C, Nathan DG. A diagnosticapproachtotheanemicpatient. In: Nathan DG, Orkin SH, editors. NathanandOski’shematology of infancyandchildhood. 5th ed. Philadelphia, PA: W.B. SaundersCo; 1998. pp. 375–84.
10.
go back to reference Rossi E, Hepcidin-theironregulatoryhormone. ClinBiochemRev. 2005;26:47–9. Rossi E, Hepcidin-theironregulatoryhormone. ClinBiochemRev. 2005;26:47–9.
11.
go back to reference Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21–2.CrossRefPubMed Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21–2.CrossRefPubMed
12.
go back to reference Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100:3776–81.CrossRefPubMed Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100:3776–81.CrossRefPubMed
13.
go back to reference Fady ME, Gendy MA, EL-Hawy AMF, Shehata HE. Osheba. Erythroferrone and iron status parameters levels in pediatric patients with iron deficiency anemia. Eur J Haematol. 2018;100:356–60.CrossRef Fady ME, Gendy MA, EL-Hawy AMF, Shehata HE. Osheba. Erythroferrone and iron status parameters levels in pediatric patients with iron deficiency anemia. Eur J Haematol. 2018;100:356–60.CrossRef
14.
go back to reference Atyaf S, Almousawi and Intisar Razzaq Sharba. Erythroferrone Hormone a Novel Biomarker is associated with Anemia and Iron Overload in Beta Thalassemia Patients. IOP Conf. Series: Journal of Physics: Conf. Series 1294 (2019) 062045. Atyaf S, Almousawi and Intisar Razzaq Sharba. Erythroferrone Hormone a Novel Biomarker is associated with Anemia and Iron Overload in Beta Thalassemia Patients. IOP Conf. Series: Journal of Physics: Conf. Series 1294 (2019) 062045.
15.
go back to reference Ganz T, Systemicironhomeostasis. PhysiolRev. 2013;93:1721–41. [PubMed: 24137020]. Ganz T, Systemicironhomeostasis. PhysiolRev. 2013;93:1721–41. [PubMed: 24137020].
17.
go back to reference Tomas Ganz Hepcidin. And the Global Burden of Iron Deficiency Clinical Chemistry 2015, 61:4: 577 – 78. Tomas Ganz Hepcidin. And the Global Burden of Iron Deficiency Clinical Chemistry 2015, 61:4: 577 – 78.
20.
21.
go back to reference Schotten N, Laarakkers CM, Roelofs RW, Origa R, vanKraaij MG, Swinkels DW. Epoandhepcidinplasmaconcentrations in blooddonorsandbetathalassemiaintermediaare not relatedtocommerciallytestedplasmaerfeconcentrations. Americanjournal of Hematology. 2017;92(3):E29–E31. Schotten N, Laarakkers CM, Roelofs RW, Origa R, vanKraaij MG, Swinkels DW. Epoandhepcidinplasmaconcentrations in blooddonorsandbetathalassemiaintermediaare not relatedtocommerciallytestedplasmaerfeconcentrations. Americanjournal of Hematology. 2017;92(3):E29–E31.
22.
go back to reference Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678 – 84. doi: 10.1038/ng.2996. Epub 2014 Jun 1. Erratum in: Nat Genet. 2020;52(4):463. PMID: 24880340; PMCID: PMC4104984. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678 – 84. doi: 10.1038/ng.2996. Epub 2014 Jun 1. Erratum in: Nat Genet. 2020;52(4):463. PMID: 24880340; PMCID: PMC4104984.
24.
go back to reference El Gendy FM, El-Hawy MA, Shehata AMF, Osheba HE. Erythroferroneandironstatusparameterslevels in pediatricpatientswithirondeficiencyanemia. Europeanjournal of Haematology. 2018;100(4):356–60. El Gendy FM, El-Hawy MA, Shehata AMF, Osheba HE. Erythroferroneandironstatusparameterslevels in pediatricpatientswithirondeficiencyanemia. Europeanjournal of Haematology. 2018;100(4):356–60.
25.
go back to reference Xu LH, Zhang Y, Wang Y, Hu D, Xu JH. HepcidinandErythroferroneLevels in Child-BearingWomenwithIronDeficiencyAnemia. 2021;29(1):213–6. Chinese. Xu LH, Zhang Y, Wang Y, Hu D, Xu JH. HepcidinandErythroferroneLevels in Child-BearingWomenwithIronDeficiencyAnemia. 2021;29(1):213–6. Chinese.
26.
go back to reference Özdemir. Nihal Irondeficiencyanemiafromdiagnosistotreatment in children Türk Ped Arş 2015; 50: 11 – 9. Özdemir. Nihal Irondeficiencyanemiafromdiagnosistotreatment in children Türk Ped Arş 2015; 50: 11 – 9.
Metadata
Title
Erythroferrone and hepcidin levels in children with iron deficiency anemia
Authors
Ramazan Dulkadir
Gamze Turna Saltoğlu
Ali Güneş
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2024
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-024-04594-5

Other articles of this Issue 1/2024

BMC Pediatrics 1/2024 Go to the issue